MAPT and Alzheimer disease: One of the key applications of MS in AD drug development is target identification and validation, where it enables the systematic identification of disease-relevant PTMs, including tau phosphorylation, Aβ glycosylation, and citrullination-related immune dysregulation (69, 70).